Home » Tenders » Americas » USA » Focused Antibody and DNA Production for CVV Investigation Tender, USA - 106131579

Focused Antibody and DNA Production for CVV Investigation Tender, USA - 106131579

HEALTH AND HUMAN SERVICES, DEPARTMENT OF | CENTERS FOR DISEASE CONTROL AND PREVENTION has floated a tender for Focused Antibody and DNA Production for CVV Investigation. The project location is USA and the tender is closing on 27 Aug 2024. The tender notice number is 75D30124Q78087, while the TOT Ref Number is 106131579. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Procurement Summary

Country : USA

Summary : Focused Antibody and DNA Production for CVV Investigation

Deadline : 27 Aug 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 106131579

Document Ref. No. : 75D30124Q78087

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Tender Details

Description

CDC Influenza Division (ID) is responsible for the development of Candidate Vaccine Viruses (CVV) based on circulating and novel influenza strains. CVVs are reassortant viruses which are used as the starting materials for seasonal and pandemic vaccines. To facilitate the development of CVVs, the CDC uses synthetic genes to transcribe viral genes to produce CVVs. Interactions between viruses and host proteins can elucidate molecular properties of viruses not readily apparent by other means. Expressing proteins from engineered plasmids is the foundation of most downstream assays utilized in this regard.

Accordingly, the Influenza Division requires synthetic genes, produced by de novo synthesis or modifications of existing templates through mutagenesis, and other genetic products to be developed routinely based on the constant changes in the genetic makeup of the circulating and novel viruses. These changes are unpredictable and cannot be identified until the viruses are isolated from patients or infected animals.
Active Contract Opportunity
Notice ID : 75D30124Q78087
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : CENTERS FOR DISEASE CONTROL AND PREVENTION
Office: CDC OFFICE OF ACQUISITION SERVICES
General Information
Contract Opportunity Type: Combined Synopsis/Solicitation (Updated)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Updated Published Date: Aug 21, 2024 07:41 am EDT
Original Published Date: Aug 02, 2024 09:13 am EDT
Updated Date Offers Due: Aug 27, 2024 04:00 pm EDT
Original Date Offers Due: Aug 21, 2024 05:00 pm EDT
Inactive Policy: 15 days after date offers due
Updated Inactive Date: Sep 11, 2024
Original Inactive Date: Sep 05, 2024
Initiative: None

Classification
Original Set Aside:

Product Service Code: 6550 - IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
NAICS Code: 325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance: Atlanta, GA USA